Shares of Argos Therapeutics Inc (NASDAQ:ARGS) saw unusually-high trading volume on Thursday . Approximately 921,330 shares were traded during trading, an increase of 397% from the previous session’s volume of 185,206 shares.The stock last traded at $5.33 and had previously closed at $6.46.

ARGS has been the subject of a number of research reports. Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 target price on shares of Argos Therapeutics in a research report on Monday, June 20th. Stifel Nicolaus cut their target price on shares of Argos Therapeutics from $16.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, March 30th. FBR & Co reiterated a “buy” rating on shares of Argos Therapeutics in a research report on Tuesday, June 14th. Zacks Investment Research upgraded shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a research report on Friday, April 1st. Finally, Roth Capital increased their target price on shares of Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, April 19th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $11.84.

The company’s 50-day moving average price is $6.06 and its 200-day moving average price is $5.61. The stock’s market capitalization is $139.03 million.

Argos Therapeutics (NASDAQ:ARGS) last issued its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by $0.01. Equities research analysts predict that Argos Therapeutics Inc will post ($1.74) EPS for the current fiscal year.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.